IL-2: The first effective immunotherapy for human cancer

Journal of Immunology

Volumn 192, Issue 12, 2014, Pages 5451-5458

  Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT;

ADULT; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MELANOMA; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES;

EID: 84902191817     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1490019     Document Type: Article

References (85)

1. Mitchison, N. A. 1955. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med. 102:157-177.
2. Morgan, D. A., F. W. Ruscetti, and R. G. Gallo. 1976. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007-1008.
3. Rosenberg, S. A. 2011. Cell transfer immunotherapy for metastatic solid cancer: what clinicians need to know. Nat. Rev. Clin. Oncol. 8:577-585.
4. Gillis, S., and K. A. Smith. 1977. Long term culture of tumour-specific cytotoxic T cells. Nature 268:154-156.
5. Rosenberg, S. A., S. Schwarz, and P. J. Spiess. 1978. In vitro growth of murine T cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens. J. Immunol. 121:1951-1955.
6. Strausser, J. L., and S. A. Rosenberg. 1978. In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. J. Immunol. 121:1491-1495.
7. Gillis, S., P. E. Baker, F. W. Ruscetti, and K. A. Smith. 1978. Long-term culture of human antigen-specific cytotoxic T-cell lines. J. Exp. Med. 148:1093-1098.
8. Cheever, M. A., P. D. Greenberg, and A. Fefer. 1981. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin 2. J. Immunol. 126:1318-1322.
9. Kurnick, J. T., K.-O. Grönvik, A. K. Kimura, J. B. Lindblom, V. T. Skoog, O. Sjöberg, and H. Wigzell. 1979. Long term growth in vitro of human T cell blasts with maintenance of specificity and function. J. Immunol. 122:1255-1260.
10. Rosenberg, S. A., S. Schwarz, P. J. Spiess, and J. M. Brown. 1980. In vitro growth of murine T cells. III. Method for separation of T cell growth factor (TCGF) from concanavalin A and biological activity of the resulting TCGF. J. Immunol. Methods 33:337-350.
11. Lotze, M. T., and S. A. Rosenberg. 1981. In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity. J. Immunol. 126:2215-2220.
12. Robb, R. J., R. M. Kutny, and V. Chowdhry. 1983. Purification and partial sequence analysis of human T-cell growth factor. Proc. Natl. Acad. Sci. USA 80:5990-5994.
13. Lotze, M. T., L. W. Frana, S. O. Sharrow, R. J. Robb, and S. A. Rosenberg. 1985. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J. Immunol. 134:157-166.
14. Taniguchi, T., H. Matsui, T. Fujita, C. Takaoka, N. Kashima, R. Yoshimoto, and J. Hamuro. 1983. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302:305-310.
15. Devos, R., G. Plaetinck, H. Cheroutre, G. Simons, W. Degrave, J. Tavernier, E. Remaut, and W. Fiers. 1983. Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucleic Acids Res. 11:4307-4323.
16. Rosenberg, S. A., E. A. Grimm, M. McGrogan, M. Doyle, E. Kawasaki, K. Koths, and D. F. Mark. 1984. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 223:1412-1414.
17. Rosenberg, S. A., J. J. Mulé, P. J. Spiess, C. M. Reichert, and S. L. Schwarz. 1985. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161:1169-1188.
18. Lotze, M. T., Y. L. Matory, S. E. Ettinghausen, A. A. Rayner, S. O. Sharrow, C. A. Seipp, M. C. Custer, and S. A. Rosenberg. 1985. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135:2865-2875.
19. Yron, I., T. A. Wood, Jr., P. J. Spiess, and S. A. Rosenberg. 1980. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J. Immunol. 125:238-245.
20. Grimm, E. A., A. Mazumder, H. Z. Zhang, and S. A. Rosenberg. 1982. Lymphokineactivated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155:1823-1841.
21. Grimm, E. A., K. M. Ramsey, A. Mazumder, D. J. Wilson, J. Y. Djeu, and S. A. Rosenberg. 1983. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J. Exp. Med. 157:884-897.
22. Yang, J. C., J. J. Mulé, and S. A. Rosenberg. 1986. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. J. Immunol. 137:715-722.
23. Mule, J. J., and S. A. Rosenberg. 1985. Successful adoptive immunotherapy of established metastases with lymphokine activated killer cells and recombinant interleukin-2. In Immune Responses to Metastases. R. B. Herberman, R. H. Wiltrout, and E. Gorelik, eds. CRC, Boca Raton, FL, p-69-94.
24. Rosenberg, S. A. 1985. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J. Natl. Cancer Inst. 75:595-603.
25. Ettinghausen, S. E., and S. A. Rosenberg. 1986. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res. 46:2784-2792.
26. Lafreniere, R., and S. A. Rosenberg. 1985. Successful therapy of hepatic metastases from several murine tumors using lymphokine activated killer cells and recombinant interleukin-2. Surg. Forum 36:392-394.
27. Lotze, M. T., B. R. Line, D. J. Mathisen, and S. A. Rosenberg. 1980. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J. Immunol. 125:1487-1493.
28. Rosenberg, S. A., M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, S. E. Ettinghausen, Y. L. Matory, J. M. Skibber, E. Shiloni, J. T. Vetto, et al. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313:1485-1492.
29. Lotze, M. T., A. E. Chang, C. A. Seipp, C. Simpson, J. T. Vetto, and S. A. Rosenberg. 1986. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 256:3117-3124.
30. Rosenberg, S. A., M. T. Lotze, L. M. Muul, A. E. Chang, F. P. Avis, S. Leitman, W. M. Linehan, C. N. Robertson, R. E. Lee, J. T. Rubin, et al. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokineactivated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316:889-897.
31. Rosenberg, S. A., M. T. Lotze, J. C. Yang, S. L. Topalian, A. E. Chang, D. J. Schwartzentruber, P. Aebersold, S. Leitman, W. M. Linehan, C. A. Seipp, et al. 1993. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85:622-632.
32. Rosenberg, S. A., J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using highdose bolus interleukin 2. JAMA 271:907-913.
33. Rosenberg, S. A., J. C. Yang, D. E. White, and S. M. Steinberg. 1998. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228:307-319.
34. Yang, J. C., R. M. Sherry, S. M. Steinberg, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, D. E. White, et al. 2003. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21:3127-3132.
35. Weber, J. S., J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, D. E. White, and S. A. Rosenberg. 1992. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 10:33-40.
36. Dillman, R. O., C. Church, R. K. Oldham, W. H. West, L. Schwartzberg, and R. Birch. 1993. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 71:2358-2370.
37. Fyfe, G. A., R. I. Fisher, S. A. Rosenberg, M. Sznol, and D. R. Parkinson. 1996. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 14:2410-2411.
38. Klapper, J. A., S. G. Downey, F. O. Smith, J. C. Yang, M. S. Hughes, U. S. Kammula, R. M. Sherry, R. E. Royal, S. M. Steinberg, and S. A. Rosenberg. 2008. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113:293-301.
39. Atkins, M. B., M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, et al. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17:2105-2116.
40. Schwartzentruber, D. J. 1995. Biologic therapy with interleukin-2: clinical applications. Principles of administration and management of side effects. In Biologic Therapy of Cancer, 2nd ed. V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg, eds. Lippincott Williams & Wilkins, Philadelphia, p-235-249.
41. Klempner, M. S., R. Noring, J. W. Mier, and M. B. Atkins. 1990. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N. Engl. J. Med. 322:959-965.
42. Bock, S. N., R. E. Lee, B. Fisher, J. T. Rubin, D. J. Schwartzentruber, J. P. Wei, D. P. E. Callender, J. C. Yang, M. T. Lotze, P. A. Pizzo, and S. A. Rosenberg. 1990. A prospective randomized trial evaluating prophylactic antibiotics to prevent triplelumen catheter-related sepsis in patients treated with immunotherapy. J. Clin. Oncol. 8:161-169.
43. Kammula, U. S., D. E. White, and S. A. Rosenberg. 1998. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83:797-805.
44. Rosenberg, S. A., and W. D. Terry. 1977. Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. 25:323-388.
45. Baker, P. E., S. Gillis, and K. A. Smith. 1979. Monoclonal cytolytic T-cell lines. J. Exp. Med. 149:273-278.
46. Rosenberg, S. A., P. J. Spiess, and S. Schwarz. 1980. In vitro growth of murine T cells. IV. Use of T-cell growth factor to clone lymphoid Cell. Immunol. 54:293-306.
47. Lotze, M. T., J. L. Strausser, and S. A. Rosenberg. 1980. In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells. J. Immunol. 124:2972-2978.
48. Greenberg, P. D., M. A. Cheever, and A. Fefer. 1981. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1122 lymphocytes. J. Exp. Med. 154:952-963.
49. Mathisen, D. J., and S. A. Rosenberg. 1980. Comparison of in vivo cell distribution following either intraperitoneal or intravenous injection of lymphoid cells. Transplantation 29:347-349.
50. Fisher, B., B. S. Packard, E. J. Read, J. A. Carrasquillo, C. S. Carter, S. L. Topalian, J. C. Yang, P. Yolles, S. M. Larson, and S. A. Rosenberg. 1989. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7:250-261.
51. Rosenstein, M., T. Eberlein, M. M. Kemeny, P. H. Sugarbaker, and S. A. Rosenberg. 1981. In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor. J. Immunol. 127:566-571.
52. Eberlein, T. J., M. Rosenstein, and S. A. Rosenberg. 1982. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J. Exp. Med. 156:385-397.
53. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321.
54. Muul, L. M., P. J. Spiess, E. P. Director, and S. A. Rosenberg. 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138:989-995.
55. Topalian, S. L., L. M. Muul, D. Solomon, and S. A. Rosenberg. 1987. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 102:127-141.
56. Topalian, S. L., D. Solomon, F. P. Avis, A. E. Chang, D. L. Freerksen, W. M. Linehan, M. T. Lotze, C. N. Robertson, C. A. Seipp, P. Simon, et al. 1988. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6:839-853.
57. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319:1676-1680.
58. Griffith, K. D., E. J. Read, J. A. Carrasquillo, C. S. Carter, J. C. Yang, B. Fisher, P. Aebersold, B. S. Packard, M. Y. Yu, and S. A. Rosenberg. 1989. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J. Natl. Cancer Inst. 81:1709-1717.
59. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumorinfiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159-1166.
60. Schwartzentruber, D. J., S. S. Hom, R. Dadmarz, D. E. White, J. R. Yannelli, S. M. Steinberg, S. A. Rosenberg, and S. L. Topalian. 1994. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 12:1475-1483.
61. Rosenberg, S. A., P. M. Aebersold, K. Cornetta, A. Kasid, R. A. Morgan, R. Moen, E. M. Karson, M. T. Lotze, J. C. Yang, S. L. Topalian, et al. 1990. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumorinfiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323:570-578.
62. Dudley, M. E., J. Wunderlich, M. I. Nishimura, D. Yu, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, R. Sherry, et al. 2001. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24:363-373.
63. Dudley, M. E., J. R. Wunderlich, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. M. Sherry, F. M. Marincola, S. F. Leitman, C. A. Seipp, et al. 2002. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25:243-251.
64. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854.
65. Dudley, M. E., J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26:5233-5239.
66. Rosenberg, S. A., J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17:4550-4557.
67. Besser, M. J., R. Shapira-Frommer, O. Itzhaki, A. J. Treves, D. B. Zippel, D. Levy, A. Kubi, N. Shoshani, D. Zikich, Y. Ohayon, et al. 2013. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 19:4792-4800.
68. Radvanyi, L. G., C. Bernatchez, M. Zhang, P. S. Fox, P. Miller, J. Chacon, R. Wu, G. Lizee, S. Mahoney, G. Alvarado, et al. 2012. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 18:6758-6770.
69. Pilon-Thomas, S., L. Kuhn, S. Ellwanger, W. Janssen, E. Royster, S. Marzban, R. Kudchadkar, J. Zager, G. Gibney, V. K. Sondak, et al. 2012. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J. Immunother. 35:615-620.
70. Gattinoni, L., D. J. Powell, Jr., S. A. Rosenberg, and N. P. Restifo. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6:383-393.
71. Yao, X., M. Ahmadzadeh, Y. C. Lu, D. J. Liewehr, M. E. Dudley, F. Liu, D. S. Schrump, S. M. Steinberg, S. A. Rosenberg, and P. F. Robbins. 2012. Levels of peripheral CD41FoxP31 regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119:5688-5696.
72. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458-6462.
73. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515-3519.
74. Robbins, P. F., Y. C. Lu, M. El-Gamil, Y. F. Li, C. Gross, J. Gartner, J. C. Lin, J. K. Teer, P. Cliften, E. Tycksen, et al. 2013. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19:747-752.
75. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129.
76. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, et al. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-546.
77. Vogelstein, B., N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz, Jr., and K. W. Kinzler. 2013. Cancer genome landscapes. Science 339:1546-1558.
78. Robbins, P. F., R. A. Morgan, S. A. Feldman, J. C. Yang, R. M. Sherry, M. E. Dudley, J. R. Wunderlich, A. V. Nahvi, L. J. Helman, C. L. Mackall, et al. 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29:917-924.
79. Parkhurst, M. R., J. C. Yang, R. C. Langan, M. E. Dudley, D. A. Nathan, S. A. Feldman, J. L. Davis, R. A. Morgan, M. J. Merino, R. M. Sherry, et al. 2011. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19:620-626.
80. Morgan, R. A., J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18:843-851.
81. Kochenderfer, J. N., W. H. Wilson, J. E. Janik, M. E. Dudley, M. Stetler-Stevenson, S. A. Feldman, I. Maric, M. Raffeld, D. A. Nathan, B. J. Lanier, et al. 2010. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:4099-4102.
82. Kochenderfer, J. N., and S. A. Rosenberg. 2013. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10:267-276.
83. + T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70:6725-6734.
84. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10:909-915.
85. Prieto, P. A., J. C. Yang, R. M. Sherry, M. S. Hughes, U. S. Kammula, D. E. White, C. L. Levy, S. A. Rosenberg, and G. Q. Phan. 2012. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res. 18:2039-2047